Key facts
- Eli Lilly presented detailed trial data for its experimental obesity drug retatrutide, suggesting it offers the greatest weight loss prospects.
- Competitors including Roche, AstraZeneca, and Pfizer also presented new data on their obesity drug candidates at the American Diabetes Association meeting.
- Analysts believe Lilly's next-generation products are superior to current weight-loss drugs and those presented by rivals.
- Eli Lilly's stock rose 1.6% on Monday, while shares of Novo Nordisk, Roche, Pfizer, and Zealand Pharma declined.
Eli Lilly has reinforced its leading position in the obesity drug market, presenting detailed data from trials of its experimental drug retatrutide. The company's findings suggest its drug could offer the most significant weight loss among current and pipeline treatments.
At the American Diabetes Association meeting in New Orleans, rivals such as Roche, AstraZeneca, and Pfizer also shared new data, indicating a growing competitive landscape. However, analysts suggest that while these competitors' drugs are on par with existing treatments, Lilly's next-generation products are set to offer greater efficacy.
Roche highlighted its dual-acting drug enicepatide, which showed a 22.7% bodyweight loss in a mid-stage trial, and its amylin-based drug petrelintide, noted for its tolerability. AstraZeneca is focusing on its oral GLP-1 drug elecoglipron as part of a broader obesity strategy. Novo Nordisk aims to offer multiple options to cater to a diverse patient population.
A key challenge in the obesity drug market remains the side effect profile, particularly gastrointestinal issues like nausea and vomiting, which can lead to high discontinuation rates. Companies are exploring amylin-based drugs to improve tolerability, with Lilly and Pfizer among those working on such therapies. Novo Nordisk's Cagrisema, a combination drug, did not meet weight-loss expectations.